Biotech binary events are some of the highest-risk, highest-reward setups in the market. But most retail traders walk in blind.

Here's the framework I use before touching any clinical catalyst play:

1. Understand what phase the trial is in

Phase 1 ≠ Phase 3. A Phase 1 readout is a safety signal, not an efficacy signal. The market often misprices this. Phase 3 failures can drop a stock 80%+ overnight. Phase 1 failures might only move it 20%. Know which one you're in.

2. Look at historical success rates by indication

Oncology has some of the lowest overall approval rates (~5-7% from Phase 1 to approval). Rare disease can be 2-3x higher due to accelerated pathways and unmet need premiums. The indication matters as much as the drug.

3. Map the FDA calendar, not just the trial readout

PDUFA dates, CRL risk, AdCom votes — these are separate catalysts that happen after a successful trial. A drug can pass Phase 3 and still get a Complete Response Letter. Most retail traders don't even know what a CRL is.

4. Dilution is the silent killer

Small-cap biotechs almost always need to raise capital. Check the cash runway, the ATM shelf registration, and recent 8-K filings. A 30% pop from a positive readout can be entirely offset by a surprise secondary offering a week later.

5. Don't size into a binary without a plan

Position sizing and defined exit levels (both up AND down) before the news hits. Once the catalyst drops, emotions take over. Your plan has to be set beforehand.

This is the kind of framework we run every day at ClinicalAlpha — AI-assisted, pre-market, focused on what actually moves the needle.